Deudextromethorphan clinical trials
Counted the way a researcher would: Deudextromethorphan with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses deudextromethorphan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2015 (5)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 5 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 0
Otsuka Pharmaceutical Development & Commercialization, Inc. (13)
Often tested with
Tested in the same studies.
Quinidine (13) · Dextromethorphan - quinidine combination (1) · Paroxetine (1) · Duloxetine (1)
Studies
Open first, then newest update. How each study uses deudextromethorphan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of SchizophreniaTerminatedPhase 2/3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT03896945Written as AVP-786
- Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual SchizophreniaCompletedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02477670Written as AVP-786
- Safety, Tolerability and Efficacy of AVP-786 for the Treatment of DisinhibitionTerminatedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02534038Written as AVP-786
- A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy VolunteersCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02174835Written as AVP-786
- Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult SubejctsCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02402595Written as AVP-786
- A Phase 1 Study Comparing AVP-786 With AVP-923CompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02336347Written as AVP-786
- Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeTerminatedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02446132Written as AVP-786
- Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeTerminatedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT04464564Written as AVP-786
- Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeTerminatedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT04408755Written as AVP-786
- Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeCompletedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT03393520Written as AVP-786
- Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeCompletedPhase 3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02442765Written as AVP-786
- Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive DisorderTerminatedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT03420222Written as AVP-786
- A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy SubjectsCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02174822Written as AVP-786
Codes
What other systems call deudextromethorphan · ClinicalTrials.gg INT019035
- UNII (FDA) 427476LZFTDEUDEXTROMETHORPHANConfirmed FDA, Wikidata
- RxNorm 2569466One source FDA
- Wikidata Q27258502deudextromethorphanConfirmed FDA, Wikidata
- NCI Thesaurus C166711DeudextromethorphanOne source FDA
- DrugBank DB19054One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 427476LZFT | DEUDEXTROMETHORPHAN | Confirmed FDA, Wikidata |
| RxNorm | 2569466 | — | One source FDA |
| Wikidata | Q27258502 | deudextromethorphan | Confirmed FDA, Wikidata |
| NCI Thesaurus | C166711 | Deudextromethorphan | One source FDA |
| DrugBank | DB19054 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.